Doripenem
drugOn this page
Also known as DoribaxS-4661SID50112763SID144206061SID170465085DORIPENEM (MONOHYDRATE)DoripenemÊDoripenemÂ
Summary
Doripenem (CHEMBL491571) is an approved small molecule (ATC J01DH04); indicated across 11 conditions including urinary tract infection and pyelonephritis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01DH04
- Indications: 11 conditions
- Clinical trials: 24
- Chemistry: 420.5 Da · C15H24N4O6S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL491571 |
| Name | Doripenem |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 73303 |
| ATC | J01DH04 |
| Molecular formula | C15H24N4O6S2 |
| Molecular weight | 420.5 |
| InChIKey | AVAACINZEOAHHE-VFZPANTDSA-N |
SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O
IUPAC name: (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Also known as: Doribax, Doripenem, S-4661, doripenem, DORIPENEM, SID50112763, SID144206061, SID170465085, DORIPENEM (MONOHYDRATE), DoripenemÊ, Doripenem (monohydrate), DoripenemÂ
Parent form; salt/anhydrous children: CHEMBL1276416, CHEMBL4303454
Patent coverage: 3,321 distinct patent families (13,372 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Voltage-dependent L-type calcium channel subunit alpha-1C, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CACNA1C | 5.7 | IC50 | 1995 | nM | CHEMBL_ACT_15258113 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| urinary tract infection | 4 | MONDO:0100338 | EFO:0003103 |
| pyelonephritis | 4 | MONDO:0006939 | EFO:1001141 |
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| pneumonia | 3 | MONDO:0005249 | EFO:0003106 |
| pancreatitis | 3 | MONDO:0004982 | EFO:0000278 |
| appendicitis | 3 | MONDO:0005649 | EFO:0007149 |
| infectious peritonitis | 3 | MONDO:0004522 | EFO:0008588 |
| cholecystitis | 3 | MONDO:0002155 | HP:0001082 |
| meningitis | 1 | MONDO:0021108 | MONDO:0021108 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 24.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 11 |
| PHASE4 | 6 |
| PHASE2 | 3 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00965848 | PHASE4 | COMPLETED | A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections |
| NCT00986102 | PHASE4 | COMPLETED | PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region |
| NCT01027897 | PHASE4 | COMPLETED | Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients |
| NCT01311141 | PHASE4 | COMPLETED | Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1 |
| NCT01401010 | PHASE4 | COMPLETED | Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients |
| NCT01467648 | PHASE4 | COMPLETED | The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia |
| NCT00210938 | PHASE3 | COMPLETED | Doripenem in the Treatment of Complicated Intra-Abdominal Infections |
| NCT00210990 | PHASE3 | COMPLETED | Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis |
| NCT00211003 | PHASE3 | COMPLETED | Doripenem in the Treatment of Hospital-Acquired Pneumonia |
| NCT00211016 | PHASE3 | COMPLETED | Doripenem in the Treatment of Ventilator-Associated Pneumonia |
| NCT00229060 | PHASE3 | COMPLETED | Doripenem in the Treatment of Complicated Intra-Abdominal Infections |
| NCT00589693 | PHASE3 | TERMINATED | To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia |
| NCT01110382 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections |
| NCT01110408 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections |
| NCT01110421 | PHASE3 | TERMINATED | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia |
| NCT01595438 | PHASE3 | COMPLETED | Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) |
| NCT01599806 | PHASE3 | COMPLETED | Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) |
| NCT02134106 | PHASE2/PHASE3 | WITHDRAWN | Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria |
| NCT00502801 | PHASE2 | COMPLETED | An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia |
| NCT00515034 | PHASE2 | COMPLETED | A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia |
| NCT01281462 | PHASE2 | COMPLETED | Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections |
| NCT00925392 | PHASE1 | COMPLETED | Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects |
| NCT01366651 | PHASE1 | TERMINATED | A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age |
| NCT01381848 | PHASE1 | COMPLETED | A Study of Doripenem in Infants Less Than 12 Weeks of Age |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).